Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,796.00
(
0.00%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
109.75
(
2.97%
)
Bitcoin
70,173.45
(
-1.50%
)
News Focus
News Focus

Replies to post #168778 on Biotech Values

Replies to #168778 on Biotech Values
icon url

DewDiligence

10/25/13 9:23 AM

#168779 RE: ronpopeil #168778

GILD now has a Sofosbuvir pricing dilemma re GT2 vs GT3!
icon url

DewDiligence

10/25/13 3:16 PM

#168792 RE: ronpopeil #168778

GILD—The “new data” on 16w of treatment with Sofosbuvir + ribavirin in treatment-naïve GT3 was not real data from a clinical trial, but rather a mathematical extrapolation by the FDA of GILD’s phase-2 data in treatment-experienced GT3 patients (see page 8 of the FDA briefing doc at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371876.pdf ). This nuance was missed by the streams I follow on Twitter.